Gapping up
In reaction to strong earnings/guidance: SKUL +22.5%, BIG +15.5%, EBS +5.5%, FL +5.2%, KFY +4.8%, CMTL +4.3%, PNY +3.8%, IPWR +2.7%, ASTI(F) +2.7%, PRTS +2%, JMBA +1.6%, QIHU +1.3%, XGTI +1.1%.
M&A news: AUQ +2.9% (announced tender offer for any and all of its outstanding 3.50% convertible notes due 2016; announces offering of $300 mln senior notes due 2022), TRQ +1.4% (seeing reports that Rio Tinto is considering making a bid for the company).
Other news: DLIA +10.9% (Tiger Global Management files 13G noting 6.3% stake), GURE +8.8% (still checking), INCY +3.6% (reports positive top-line results from Phase III study of Ruxolitinib in patients with polycythemia vera), PLUG +3.3% (CEO to make appearance on CNBC later today), GOGO +2.9% (S.A.C. Capital disclosed 5.1% passive stake), SGMO +2.8% (mentioned positively by Jim Cramer; co's CEO made appearance on Mad Money.
Analyst comments: CNAT +7.3% (initiated with a Buy at ROTH Capital), GTAT +6.6% (upgraded to Outperform from Neutral at Credit Suisse), CCRN +6.4% (upgraded to Buy from Neutral at Citigroup, upgraded to Buy from Hold at Cantor Fitzgerald), TFM +4.4% (upgraded to Buy from Neutral at UBS), PVG +2.4% (resumed with an Outperform at BMO Capital Mkts ), PLCM +2.2% (upgraded to Buy from Neutral at Citigroup), YELP +1.7% (target raised to $115 at Pacific Crest), TEVA +1.6% (upgraded to Overweight from Equal Weight at Barclays), CLH +1% (upgraded to Strong Buy from Mkt Perform at Raymond James
)
In reaction to strong earnings/guidance: SKUL +22.5%, BIG +15.5%, EBS +5.5%, FL +5.2%, KFY +4.8%, CMTL +4.3%, PNY +3.8%, IPWR +2.7%, ASTI(F) +2.7%, PRTS +2%, JMBA +1.6%, QIHU +1.3%, XGTI +1.1%.
M&A news: AUQ +2.9% (announced tender offer for any and all of its outstanding 3.50% convertible notes due 2016; announces offering of $300 mln senior notes due 2022), TRQ +1.4% (seeing reports that Rio Tinto is considering making a bid for the company).
Other news: DLIA +10.9% (Tiger Global Management files 13G noting 6.3% stake), GURE +8.8% (still checking), INCY +3.6% (reports positive top-line results from Phase III study of Ruxolitinib in patients with polycythemia vera), PLUG +3.3% (CEO to make appearance on CNBC later today), GOGO +2.9% (S.A.C. Capital disclosed 5.1% passive stake), SGMO +2.8% (mentioned positively by Jim Cramer; co's CEO made appearance on Mad Money.
Analyst comments: CNAT +7.3% (initiated with a Buy at ROTH Capital), GTAT +6.6% (upgraded to Outperform from Neutral at Credit Suisse), CCRN +6.4% (upgraded to Buy from Neutral at Citigroup, upgraded to Buy from Hold at Cantor Fitzgerald), TFM +4.4% (upgraded to Buy from Neutral at UBS), PVG +2.4% (resumed with an Outperform at BMO Capital Mkts ), PLCM +2.2% (upgraded to Buy from Neutral at Citigroup), YELP +1.7% (target raised to $115 at Pacific Crest), TEVA +1.6% (upgraded to Overweight from Equal Weight at Barclays), CLH +1% (upgraded to Strong Buy from Mkt Perform at Raymond James
)